Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–42 of 42 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Sildenafil 20 MG Clear all
Completed Phase 1Phase 2 Interventional Results available

Study of Sildenafil Citrate on Insulin Resistance in African American

NCT01334554
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available

Study of Add-on Ambrisentan Therapy to Background Phosphodiesterase Type-5 Inhibitor (PDE5i) Therapy in Pulmonary Arterial Hypertension (ATHENA-1)

NCT00617305
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Ambrisentan, Placebo, Sildenafil, Tadalafil
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
16 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
30
States / cities
Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Sep 30, 2026, 6:01 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Early Pulmonary Vascular Disease in Scleroderma

NCT04797286
View directory record Official record
Conditions
Scleroderma, Mildly Elevated Pulmonary Pressures
Interventions
Sildenafil, Placebo
Drug · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
New Orleans, Louisiana • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

Pharmacokinetic Effects of QTI571 on Sildenafil and Bosentan in Pulmonary Arterial Hypertension Participants

NCT01392469
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Imatinib, Sildenafil, Bosentan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
Tampa, Florida • Weston, Florida • Mineola, New York
Source: ClinicalTrials.gov public record
Updated Jun 21, 2021 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Sildenafil Citrate Used in Combination With Intravenous Epoprostenol in PAH

NCT00159861
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
16 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
33
States / cities
La Jolla, California • Los Angeles, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 4 Interventional

Characterization of LV Strain Patterns in Mildly Elevated PCWP and PAH.

NCT01800292
View directory record Official record
Conditions
Hypertension, Pulmonary Artery, Ventricular Dysfunction, Left
Interventions
sildenafil
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 80 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 4, 2015 · Synced Sep 30, 2026, 6:01 AM EDT
Terminated Phase 4 Interventional Results available

Effects of Oral Sildenafil on Mortality in Adults With PAH

NCT02060487
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years to 74 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
11
States / cities
Atlanta, Georgia • Grand Rapids, Michigan • Wooster, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 13, 2022 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Blood Flow and Vascular Function in Cystic Fibrosis

NCT02057458
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Sildenafil (Acute-1 hour), Sildenafil (Subchronic-4 weeks), Placebo
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 24, 2020 · Synced Sep 30, 2026, 6:01 AM EDT
Terminated Phase 4 Interventional Results available

To Assess The Efficacy and Safety Of Oral Sildenafil in the Treatment of Pulmonary Arterial Hypertension.

NCT00430716
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sildenafil citrate
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
15
States / cities
Phoenix, Arizona • Augusta, Georgia • Decatur, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Assess the Effect of Daily Treatment of Vardenafil 20mg or Sildenafil 100mg and Placebo on Sperm Function

NCT00655590
View directory record Official record
Conditions
Erectile Dysfunction
Interventions
Levitra (Vardenafil, BAY38-9456), Sildenafil, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
25 Years to 64 Years · Male only
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
18
States / cities
Phoenix, Arizona • Tempe, Arizona • Beverly Hills, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for the Treatment of Lymphatic Malformations

NCT02335242
View directory record Official record
Conditions
Lymphatic Malformations, Lymphatic Diseases
Interventions
Sildenafil 20 mg tablets, Placebo tablets (resembling Revatio)
Drug · Other
Lead sponsor
Stanford University
Other
Eligibility
6 Months to 10 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2022 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Sildenafil for Treatment of Choroidal Ischemia

NCT04356716
View directory record Official record
Conditions
Choroidal Ischemia, Vitelliform Macular Dystrophy, Age-related Macular Degeneration, Central Serous Retinopathy, Retinitis Pigmentosa
Interventions
Sildenafil, Standard of Care Sildenafil, Ocular Coherence Tomography-Angiography (OCT-A), Visual Acuity (VA)
Drug · Other · Diagnostic Test
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 4, 2025 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Results available

Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

NCT02891850
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Riociguat (Adempas, BAY63-2521), Sildenafil, Tadalafil
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Tucson, Arizona • Sacramento, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2021 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Not applicable Interventional Results available

Effect of Sildenafil on Diffusion Capacity in Patients With PH and Parenchymal Lung Disease

NCT01948518
View directory record Official record
Conditions
Diffuse Parenchymal Lung Disease, Pulmonary Hypertension
Interventions
Oral sildenafil 20 mg
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2014 · Synced Sep 30, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional Results available

A Research Study To Assess The Effectiveness And Safety Of Different Doses Of Oral PF-00489791 In The Treatment Of Adult Patients With Pulmonary Arterial Hypertension

NCT00853112
View directory record Official record
Conditions
Hypertension, Pulmonary
Interventions
PF-00489791, placebo, sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Phoenix, Arizona • Gainesville, Florida • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2017 · Synced Sep 30, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

Sildenafil Trial of Exercise Performance in Idiopathic Pulmonary Fibrosis

NCT00517933
View directory record Official record
Conditions
Pulmonary Fibrosis, Hypertension, Pulmonary
Interventions
Sildenafil Citrate, Placebo
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
13
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Sep 30, 2026, 6:01 AM EDT
Recruiting Phase 2 Interventional

Sildenafil for Microvasculopathy in Chronic TBI

NCT05782244
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Sildenafil Citrate low dose, Placebo, Sildenafil medium dose, Sildenafil high dose
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 10, 2025 · Synced Sep 30, 2026, 6:01 AM EDT
Withdrawn Not applicable Interventional

Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

NCT01812434
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Sep 30, 2026, 6:01 AM EDT